Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing therapies that target Natural Killer T (NKT) cells for the treatment of inflammatory, fibrotic and autoimmune diseases. This news page aggregates company announcements, clinical updates and capital markets disclosures related to GRI Bio and the GRI stock.
Investors following GRI Bio’s news can track the progress of its lead program GRI-0621, an oral RARβγ agonist and iNKT activity inhibitor being developed for idiopathic pulmonary fibrosis (IPF). The company has reported interim and topline results from a Phase 2a randomized, double-blind, placebo-controlled trial in IPF, including safety and tolerability data, changes in collagen turnover biomarkers, signals of alveolar basement membrane repair and analyses of forced vital capacity (FVC). Additional releases describe immune profiling data showing iNKT inhibition and shifts toward an anti-fibrotic cytokine profile.
News items also cover interim biomarker and lung function analyses, recommendations from the Independent Data Monitoring Committee, and presentations at investor and industry conferences. These communications provide context on how GRI Bio interprets emerging clinical data and its plans for further development of GRI-0621.
Beyond clinical results, GRI Bio issues press releases on financing transactions, such as its December 2025 best efforts public offering of common stock, pre-funded warrants and Series F warrants, and related Nasdaq listing compliance updates. Governance and corporate actions, including equity incentive plan amendments and annual meeting matters, are reflected in associated SEC filings and news references.
By reviewing this GRI news feed, readers can monitor key developments in GRI Bio’s NKT cell–modulating pipeline, particularly in IPF and systemic lupus erythematosus, as well as follow capital raising activities and other material events that may be relevant to GRI stock research. Bookmark this page to access an organized stream of GRI Bio press releases and related market updates.
GRI Bio announced positive preclinical data for its lead program GRI-0621 in treating Idiopathic Pulmonary Fibrosis (IPF). The data, presented at the 2024 ATS International Conference, showed that GRI-0621 significantly reduced fibrosis and lung inflammation in a mouse model by inhibiting type 1 invariant Natural Killer T (iNKT) cell activity. The company is advancing to a Phase 2a biomarker study, with interim data expected in Q3 2024 and topline results in Q4 2024. This study will evaluate the safety, tolerability, and biomarker effects of GRI-0621 in IPF patients.
GRI-0621's mechanism involves inhibiting iNKT cells, which are pivotal in the early stages of fibrotic disease. Existing IPF treatments are and come with significant side effects, making GRI-0621 a promising candidate. GRI Bio aims to leverage the 505(b)(2) regulatory pathway to accelerate the drug's development.
GRI Bio, a biotechnology company listed on NASDAQ under the ticker GRI, will present at Alliance Global Partner’s 2024 Healthcare Company Showcase. The event is scheduled for May 21, 2024, at 2:40 PM ET. The company specializes in developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases. Marc Hertz, PhD, CEO of GRI Bio, will participate in a live webcast fireside chat. This event can be accessed through the Investors section on GRI Bio's website.
GRI Bio, Inc. reported its first quarter financial results for 2024, highlighting the progress of their lead programs GRI-0621 for Idiopathic Pulmonary Fibrosis and GRI-0803 for Systemic Lupus Erythematosus. The company is focused on advancing innovative NKT cell modulators for various diseases. The financial results showed a net loss of $1.9 million, with research and development expenses increasing compared to the previous year. GRI Bio closed a public offering in February 2024, raising $5.5 million to support ongoing operations.
GRI Bio, Inc. (NASDAQ: GRI) announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity. The company will discuss innovative treatments for inflammatory, fibrotic, and autoimmune diseases, with presentations by Chief Scientific Officer, Vipin Kumar Chaturvedi. The event will take place in Ljubljana, Slovenia on May 17-20, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.